Scinvivo B.V.

Based in Eindhoven, Netherlands, and founded in 2016, Scinvivo B. V. operates as a medical technology company offering products for bladder cancer diagnostics. In February 2024 the firm raised EUR 4.

7 million in venture funding led by investors Santec Holdings Corporation and NLC. The firm as of February 2023, is led by its CMO, Maaike de Jong, and CEO, Marijn van Os. The company offers solutions for the medical needs of bladder cancer, specializing in minimally invasive imaging platforms. This imaging platform allows real-time visualization of tissue structures below the surface with unparalleled resolution, detecting tumors as small as 1/10th of a millimeter.

This technology facilitates one-stop diagnosis and treatment, aided by AI (artificial intelligence) powered analysis to differentiate between benign and malignant tissues. Additionally, Scinvivo’s photonics-based localization enables precise robotic surgery. The firm also offers Scinvivo's OCT catheter that supports urologists with ultra-high-resolution insights during cystoscopy, crucial for distinguishing between different cancer stages and reducing unnecessary surgeries. The product includes a single-use catheter and base station, ensuring safety and accuracy.

The company plans to utilize the February 2024 funding to develop the catheter, OCT system, and software so that it is usable in clinics and appealing to urologists.